Evaluate GYRE stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in GYRE? | Glauxie AI

Q: What are the risks of investing in GYRE?

Gyre Therapeutics, Inc. (GYRE) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Ping Zhang. Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers... Employees: 200,000.

Q: How much debt does GYRE have?

Review GYRE total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is GYRE a good long-term investment?

Evaluate GYRE as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in GYRE?

🦉

Gyre Therapeutics, Inc. (GYRE)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOPing Zhang

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary...

Key Executives

Name	Title
Han Ying	Senior Vice President of Science
Jialiang Wang	Executive VP & GM
Jing Liu	Senior Vice President of Platform Chemistry
Joshua Bergmann	General Counsel & Corporate Secretary
Mark Marino	Senior Vice President of Clinical Development
Michael Plewe	Senior Vice President - Medicinal Chemistry

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

GYRE Profile Financials

Is GYRE stock safe? How much debt does GYRE have? Is GYRE a good long-term investment?